OncoMatch/Clinical Trials/NCT06475417
Neoadjuvant Adebrelimab + DOS in Locally Advanced Resectable Gastric Cancer
Is NCT06475417 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adebrelimab combined with DOS for gastric cancer.
Treatment: Adebrelimab combined with DOS — To evaluate the efficacy and safety of adebrelimab combined DOS in neoadjuvant treatment of locally advanced resectable gastric cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastric Cancer
Disease stage
Required: Stage T2-3N+M0, T4ANANYM0
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
hemoglobin (hb) ≥ 90 g/l, absolute neutrophil count (anc) ≥ 1.5 × 10^9/l, platelets (plt) ≥ 80 × 10^9/l (no recent blood transfusions within 14 days)
Kidney function
serum creatinine (cr) ≤ 1.5 × uln or creatinine clearance rate (ccr) ≥ 60 ml/min
Liver function
total bilirubin (tbil) ≤ 1.5 × upper limit of normal (uln), alanine aminotransferase (alt) and aspartate aminotransferase (ast) ≤ 2.5 × uln
Cardiac function
left ventricular ejection fraction (lvef) ≥ lower limit of normal (50%)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify